文献速递中毒与环境急症重症综合管理与镇静镇痛

比较毒扁豆碱与劳拉西泮治疗抗毒蕈碱(抗胆碱能)中毒综合征的随机试验

A randomized trial comparing physostigmine vs lorazepam for treatment of antimuscarinic (anticholinergic) toxidrome.
PubMed 文献 · Clin Toxicol (Phila) · 2020-12-09
一句话结论在青少年抗毒蕈碱中毒谵妄和激越中,毒扁豆碱负荷及4小时输注在控制谵妄和激越上优于劳拉西泮,且无严重不良事件。

该研究为盲法随机临床试验,纳入10-<18岁、具有至少1个中枢和2个外周抗毒蕈碱症状、谵妄和中度激越的患者。受试者随机接受劳拉西泮0.05 mg/kg负荷后4小时生理盐水输注,或毒扁豆碱0.02 mg/kg负荷后4小时输注(0.02 mg/kg/h)。毒扁豆碱组负荷后谵妄比例(44% vs 100%, p=0.01)和输注第4小时谵妄比例(22% vs 100%, p<0.001)均低于劳拉西泮组,激越评分下降更显著(89% vs 30%, p=0.02)。两组均无癫痫、心动过缓、支气管溢液、支气管痉挛、插管或心律失常。

要点

  • 在10-<18岁抗毒蕈碱中毒谵妄和激越患者中,毒扁豆碱0.02 mg/kg负荷后4小时输注0.02 mg/kg/h,负荷后谵妄比例44% vs 劳拉西泮100%(p=0.01)。
  • 毒扁豆碱组输注第4小时谵妄比例22% vs 劳拉西泮组100%(p<0.001)。
  • 毒扁豆碱组负荷后激越评分下降89% vs 劳拉西泮组30%(p=0.02),但输注第4小时两组无差异(p>0.99)。
  • 两组均未出现癫痫、心动过缓、支气管溢液、支气管痉挛、插管或心律失常。
  • 对于青少年抗毒蕈碱中毒所致显著谵妄和激越,应考虑毒扁豆碱负荷及输注治疗。

适用人群与场景

  • 纳入标准:年龄≥10-<18岁,至少1个中枢和2个外周抗毒蕈碱症状,谵妄和中度激越。
  • 排除标准:原文未提及。

诊断标准与关键阈值

  • 抗毒蕈碱中毒综合征诊断需至少1个中枢症状和2个外周症状,并存在谵妄和中度激越(原文未列出具体症状条目)。

处置流程与药物剂量

  • 毒扁豆碱组:毒扁豆碱0.02 mg/kg负荷(途径原文未提及),随后4小时输注毒扁豆碱0.02 mg/kg/h。
  • 劳拉西泮组:劳拉西泮0.05 mg/kg负荷(途径原文未提及),随后4小时生理盐水输注。
  • 目标:控制谵妄和激越(负荷后及输注期间)。

红旗征与不能漏的情况

  • 原文未提及需要立刻处理或不能漏诊的具体红旗征及处理。

研究设计与关键结果

  • 人群:10-<18岁抗毒蕈碱中毒综合征患者;最常见摄入药物为苯海拉明(16例,84%)。
  • 干预与对照:毒扁豆碱0.02 mg/kg负荷+4小时输注0.02 mg/kg/h vs 劳拉西泮0.05 mg/kg负荷+4小时生理盐水输注。
  • 主要终点:负荷后谵妄比例毒扁豆碱组44% vs 劳拉西泮组100%(p=0.01);输注第4小时谵妄比例22% vs 100%(p<0.001)。
  • 关键次要终点:负荷后激越评分下降毒扁豆碱组89% vs 劳拉西泮组30%(p=0.02);输注第4小时无差异(p>0.99)。
  • 不良事件:两组均无癫痫、心动过缓、支气管溢液、支气管痉挛、插管或心律失常。

证据类型、等级与局限

  • 证据类型:盲法随机临床试验;证据等级或推荐强度:原文未提及。

对床旁实践的改变

  • 对于10-<18岁抗毒蕈碱中毒所致显著谵妄和激越患者,可考虑使用毒扁豆碱负荷及4小时输注,而非仅用劳拉西泮。
  • 毒扁豆碱负荷后控制谵妄和激越优于劳拉西泮,且4小时输注期间谵妄控制更优;但输注第4小时激越评分无差异。
  • 本试验未报告严重不良事件,但样本量小,需警惕毒扁豆碱潜在不良反应(原文未提及具体监测要求)。
  • 不适用人群:年龄<10岁或≥18岁、无谵妄或仅为轻度激越、排除标准未明确者。

指南或共识出处

  • 原文未提及

以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。

英文原文(摘要)· 点击展开

BACKGROUND: Toxicity from antimuscarinic agents precipitates a constellation of signs and symptoms; two of the most significant are agitation and delirium. Benzodiazepines are commonly used for treatment; physostigmine is also effective but is underutilized due to concerns for safety and short duration of action. The objective of this study was to compare lorazepam to physostigmine for the treatment of antimuscarinic delirium and agitation.

METHODS: This was a blinded, randomized clinical trial in patients presenting for antimuscarinic toxidrome. Inclusion criteria were: ≥10-<18 years old, at least one central and two peripheral antimuscarinic symptoms, delirium and moderate agitation. Subjects were randomized to either (1) lorazepam bolus (0.05 mg/kg) followed by a 4-h normal saline infusion, or (2) physostigmine 0.02 mg/kg bolus followed by a 4-h physostigmine infusion (0.02 mg/kg/h). Primary outcomes were the control of delirium and agitation after bolus and during the infusion.

RESULTS: Ten (53%) subjects were enrolled in the lorazepam arm, 9 (47%) in the physostigmine arm. Diphenhydramine was the most common agent ingested (16, 84%). Fewer patients receiving physostigmine had delirium after the initial bolus (44% vs 100%, p = 0.01) and at the 4th hour of infusion (22% vs 100%, p < 0.001) compared to patients who received lorazepam. There was a significant decrease in agitation scores in the physostigmine arm compared to the lorazepam arm after the initial bolus (89% vs 30%, p = 0.02), but no difference at the 4th hour of infusion (p > 0.99). There were no seizures, bradycardia, bronchorrhea, bronchospasm, intubation, or cardiac dysrhythmias.

CONCLUSION: Physostigmine was superior to lorazepam in controlling antimuscarinic delirium and agitation after bolus dosing, and control of delirium after a 4-h infusion. There were no serious adverse events in either treatment arm. Physostigmine bolus and infusion should be considered in adolescent patients with significant delirium and agitation from antimuscarinic agents.

来源:Clin Toxicol (Phila),查看原文。版权归原作者所有。

参考来源

  1. Wang GS, Baker K, Ng P, et al. A randomized trial comparing physostigmine vs lorazepam for treatment of antimuscarinic (anticholinergic) toxidrome. Clin Toxicol (Phila). 2020. PMID: 33295809. doi:10.1080/15563650.2020.1854281

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。